Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE study of inhaled tobramycin duration for early Pseudomonas infection in cystic fibrosis
NL-OMON23558Active, not recruiting
- Sponsor
- Chiron Corporation
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tobramycin in Pseudomonal infection and cystic fibrosis (CF) (2 arms), sponsored by Chiron Corporation. Primary endpoint: Duration of eradication of Pseudomonas aeruginosa. Started Oct 2003; status: active, not recruiting.
02
Drugs
tobramycin
03
Conditions
Pseudomonal infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON23558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23558.